Suven Life Sciences Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022
For the six months, sales was INR 79.26 million compared to INR 31.9 million a year ago. Revenue was INR 85.68 million compared to INR 45.33 million a year ago. Net loss was INR 395.08 million compared to INR 675.07 million a year ago. Basic loss per share from continuing operations was INR 2.72 compared to INR 5.3 a year ago. Diluted loss per share from continuing operations was INR 2.72 compared to INR 5.3 a year ago.